5 research outputs found

    Design of small molecule inhibitors of CDK2 and ATAD2 for anti-cancer therapy

    No full text
    PhD ThesisIn this thesis small molecule inhibitors of the CDK2/CCNE interaction and the ATAD2 bromodomain are investigated. Dysregulation of cell cycle CDKs is a common genetic driver of multiple tumour types. Many pan-selective CDK inhibitors have failed in clinical trials due to a lack of efficacy or unanticipated toxicity. The development of highly selective inhibitors of CDK2 has been particularly challenging due to the similarity of the ATP binding site to that of CDK1. A fragment screen conducted by Astex pharmaceuticals identified a number of fragment hits which bound in an allosteric pocket of CDK2 thought to be essential for cyclin binding. A hit expansion exercise based on 23 led to the discovery of a new pocket potentially relevant to the activity of the protein. Optimisation of 22 led to the discovery of the first small molecules to displace a partner cyclin from a CDK with an EC50 < 100 µM. This represents an entirely novel strategy for the selective inhibition of CDK2. 202 is the most promising compound yet synthesised and further optimisation studies are ongoing. vi ATAD2 is a bromodomain-containing protein overexpression of which is associated with poor prognosis in multiple tumour types. A highly ligand efficient hit 218 identified by a fragment screen at Astex pharmaceuticals was shown to bind in the active site of the ATAD2 bromodomain. Despite promising molecular docking, targeting the ZA-shelf of the bromodomain by judicious substitution of the 5- position of 218 did not improve the potency of the hit. Replacement of the amino group with a series of benzimidazoles was also unsuccessful

    Design and synthesis of biphenyl and biphenyl ether inhibitors of sulfatases

    No full text
    Inhibitors of sulfatase-2 are putative anticancer agents, but the discovery of potent small molecules targeting this enzyme has proved challenging. Based on molecular modelling, two series of sulfatase-2 inhibitors have been developed with biphenyl and biphenyl ether scaffolds judiciously substituted with sulfamate, carboxylate and other polar groups (e.g. amino). Inhibition of aryl sulfatase A and B was also determined. The biphenyl ether derivatives were less selective for sulfatase-2 over aryl sulfatase B than the biphenyl series. All biphenyl ether derivatives inhibited aryl sulfatase A, whereas only amino derivatives inhibited aryl sulfatase B significantly. In the biphenyl series few derivatives exhibited activity against aryl sulfatase B. The trichloroethylsulfamate group was identified as a new pharmacophore enabling potent inhibition of all of the sulfatases studied
    corecore